This seminar will provide an overview of the CRISPR IP saga, discussion of considerations in relation to freedom-to-operate for use of the technology and an update on the lessons to be learnt from the IP issues which have inflicted major costs on those involved.
Thursday 27th June, Der Teufelhof Basel, 6pm
CRISPR gene-editing continues to hit headlines regularly as a ground-breaking technology with many millions now flowing into companies seeking to exploit the technology in both therapeutic and agricultural fields. Unfortunately the corresponding IP landscape still has many issues to be resolved with possibility of divergence between Europe and the US.
This seminar will provide an overview of the CRISPR IP saga, discussion of considerations in relation to freedom-to-operate for use of the technology and an update on the lessons to be learnt from the IP issues which have inflicted major costs on those involved.
Speakers, Dr Claire Irvine, Mike Nelson and Dr Leena Contarino, are all highly experienced patent attorneys of the Life Sciences and Pharma teams of HGF. Claire is also a partner of the HGF specialist CRISPR team involved in advising a number of companies in the gene-editing field. Mike and Leena are partner's based in HGF's Basel office.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
